Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 studyMichel Attal, Michel Pavic, Meral Beksaç et al.|The Lancet|2019Cited by 635
IgM myeloma: A multicenter retrospective study of 134 patientsJorge J. Castillo, Morie A. Gertz, Artur Jurczyszyn et al.|American Journal of Hematology|2017Cited by 49